Get started
Author

Gillian F. Watt

Observed names: G F Watt, G.F. Watt, Gillian F Watt, Gillian Watt
ORCID: 0000-0002-0855-4740
Observed ORCID: 0000-0002-0855-4740
OpenAlex ID: A5004624072
Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2
2020 · Alina Mares, Afjal H. Miah, et al. · Communications Biology · 234
PDF
Discovery and Characterisation of Highly Cooperative FAK‐Degrading PROTACs
2021 · Robert P. Law, Joao Nunes, et al. · Angewandte Chemie International Edition · 122
Structural Insights into PROTAC-Mediated Degradation of Bcl-xL
2020 · Chun-wa Chung, Han Dai, et al. · ACS Chemical Biology · 87
Optimization of a Series of RIPK2 PROTACs
2021 · Afjal H. Miah, Ian E. D. Smith, et al. · Journal of Medicinal Chemistry · 76
Targeted protein degradation in vivo with Proteolysis Targeting Chimeras: Current status and future considerations
2019 · Gillian F. Watt, Paul Scott-Stevens, et al. · Drug Discovery Today Technologies · 73
Design, Synthesis, and Structure−Activity Relationships of Novel Non-Imidazole Histamine H3 Receptor Antagonists
2000 · Ian D. Linney, Ildiko M. Buck, et al. · Journal of Medicinal Chemistry · 65
Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia
2022 · Yiman Liu, Qinglan Li, et al. · Cancer Discovery · 61
PDF
Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3Kδ
2017 · Rodger A. Allen, Daniel C. Brookings, et al. · Journal of Pharmacology and Experimental Therapeutics · 45
Evidence for PI-3K-dependent migration of Th17-polarized cells in response to CCR2 and CCR6 agonists
2008 · Adam Webb, Andrew Johnson, et al. · Journal of Leukocyte Biology · 40
Optimization of 1,3,4-Benzotriazepine-Based CCK2 Antagonists to Obtain Potent, Orally Active Inhibitors of Gastrin-Mediated Gastric Acid Secretion
2007 · Iain M. McDonald, James W. Black, et al. · Journal of Medicinal Chemistry · 36
Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI‐74330, using a murine CXCR3 internalization assay
2007 · L A Jopling, G F Watt, et al. · British Journal of Pharmacology · 20
PDF
Optimization of the in Vitro and in Vivo Properties of a Novel Series of 2,4,5-Trisubstituted Imidazoles as Potent Cholecystokinin-2 (CCK2) Antagonists
2005 · Ildiko M. Buck, James W. Black, et al. · Journal of Medicinal Chemistry · 19
Analysis of the variation in the action of L‐365,260 at CCKB/gastrin receptors in rat, guinea‐pig and mouse isolated gastric tissue assays
1996 · S.P. Roberts, E.A. Harper, et al. · British Journal of Pharmacology · 18
PDF
From histamine to imidazolylalkyl-sulfonamides: The design of a novel series of histamine H3-receptor antagonists
1999 · Matthew J. Tozer, Elaine A. Harper, et al. · Bioorganic & Medicinal Chemistry Letters · 17
Nonpeptide Cholecystokinin-2 Receptor Agonists
2001 · S. Barret Kalindjian, David J. Dunstone, et al. · Journal of Medicinal Chemistry · 16
Discovery and Characterisation of Highly Cooperative FAK‐Degrading PROTACs
2021 · Robert P. Law, Joao Nunes, et al. · Angewandte Chemie · 6
The Discovery of CDP323, a Potent Alpha4 Integrin Antagonist
2012 · Stuart Bailey, Roger Palframan, et al. · Current Immunology Reviews · 1
Discovery of Potent, Orally Bioavailable, and CNS-Penetrant 1,2,3-Triazolopyridinyl Piperazine-Based PARP1-Selective Inhibitors
2026 · Tammy Ladduwahetty, Benjamin F. Rahemtulla, et al. · Journal of Medicinal Chemistry
Discovery of a Novel P2X2/3 Allosteric Antagonist as an Efficient Bitter Taste Blocker
2026 · François Saint-Dizier, Sebastien Campos, et al. · Journal of Medicinal Chemistry
GB3226, a novel, orally active, first-in-class small molecule inhibitor of ENL-yeats and FLT3 kinase for the treatment of Relapsed/Refractory Acute Myeloid Leukemia
2025 · Louis Renzetti, Stacia Kargman, et al. · Blood
Editor’s Note: Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia
2025 · Yiman Liu, Qinglan Li, et al. · Cancer Discovery
PDF
Data from Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia
2023 · Yiman Liu, Qinglan Li, et al.
Supplementary Data from Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia
2023 · Yiman Liu, Qinglan Li, et al.
Supplementary Data from Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia
2023 · Yiman Liu, Qinglan Li, et al.
Supplementary Data from Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia
2023 · Yiman Liu, Qinglan Li, et al.
Works count: 34
Citation count: 936
H-index: 15
I10-index: 15
Year
Topic
Type